ENDRA Life Sciences Inc.: insider trades · United States · SEC (Form 4)

About ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc. is a U.S.-based medical technology company listed on Nasdaq (United States), focused on biomarker imaging and non-invasive solutions for assessing liver and tissue fat content. The company is centered on its proprietary Thermo Acoustic Enhanced Ultrasound (TAEUS®) platform, which combines thermo-acoustic and ultrasound principles to measure tissue fat, with its primary commercial and clinical focus on liver fat quantification. ENDRA is headquartered in Ann Arbor, Michigan, and its market position is that of a niche, pre-commercial challenger targeting a very large but still underserved global diagnostic need. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and?utm_source=openai)) From a historical perspective, ENDRA built its capabilities around imaging and tissue measurement technologies before narrowing its strategic emphasis to the early detection and monitoring of steatotic liver disease, including MASLD and MASH. That shift is important from an equity research perspective because it moves the company toward a high-unmet-need clinical area where better diagnostics could have meaningful adoption if performance, reimbursement, and regulatory requirements are met. In 2025, ENDRA also disclosed an expanded business strategy that includes a digital asset treasury initiative, which adds a less conventional financial layer to its corporate profile and increases the complexity of the investment case. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-provides-business-update-and-reports-first-quarter-2025-financial?utm_source=openai)) The core product story remains TAEUS®, particularly TAEUS Liver, which is being developed to quantify liver fat at the point of care and, in some applications, to support monitoring during minimally invasive ablation procedures. Recent company updates have highlighted feasibility-study and pilot-study results indicating progress in accuracy, repeatability, and alignment with MRI-based benchmarks. For investors, this suggests technical momentum, but not yet a fully de-risked commercialization path. The key watchpoints are still clinical validation, regulatory clearance, and the ability to prove a practical workflow advantage versus established imaging modalities. ([businesswire.com](https://www.businesswire.com/news/home/20250616575045/en/ENDRAs-Ongoing-Multisite-Pilot-Study-Reveals-Important-Enhancements-to-Boost-TAEUS-Liver-Accuracy-and-Repeatability-Against-MRI-Gold-Standard?utm_source=openai)) Competitively, ENDRA operates in a field dominated by larger, better-capitalized medical imaging and diagnostic players. Its potential advantage is an easier, lower-cost, point-of-care approach that could improve access compared with more resource-intensive reference methods. However, ENDRA’s small-cap status also means elevated execution risk: the company has been managing tight liquidity, has raised capital through private placements, and has continued to rely on external financing while pursuing product and clinical milestones. Public filings and corporate updates in 2025 and 2026 also point to ongoing strategic review activity by the board, underscoring the company’s focus on maximizing shareholder value. ([businesswire.com](https://www.businesswire.com/news/home/20251117008793/en/ENDRA-Life-Sciences-Recaps-Major-Milestones-and-New-Strategic-Initiatives-Announces-Third-Quarter-2025-Financial-Results?utm_source=openai)) Geographically, ENDRA is a U.S. company with headquarters in Michigan, but its target market is global if the technology ultimately achieves broader regulatory and commercial acceptance. In short, ENDRA Life Sciences is a Nasdaq-listed U.S. health-tech micro-cap with a differentiated diagnostic platform, meaningful long-term upside if development succeeds, and substantial financing and commercialization risk in the near term. ([nasdaq.com](https://www.nasdaq.com/press-release/endra-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and?utm_source=openai))